The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Crohn's Disease

In brief

It is hypothesized that oral naltrexone will improve inflammation of the bowel by increasing endogenous enkephalin levels in subjects with active Crohn's disease. This is especially important in children who often are suffering from nutritional deprivation which retards their growth. The key objectives are to: 1. Evaluate the effects of low dose naltrexone in children with Crohn's Disease by using the Pediatric Crohn's Disease Activity Index (PCDAI), plasma inflammatory markers, weight, and pediatric quality of life survey. 2. To determine the safety and toxicity of low dose naltrexone in pediatric subjects with active Crohn's Disease. 3. Assess the potential mechanism by which naltrexone exerts its action by measuring plasma opioid (enkephalin and endorphin levels) and proinflammatory cytokines.

Key facts

Study ID

NCT00715117

Run by

Milton S. Hershey Medical Center

People needed

14

Starts

2008-07-01

Expected to finish

2010-08-01

Last updated by the study team

2018-09-06

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All subjects must give written informed consent by parent or guardian
• Male or female subjects, > 6 - 17 years
• Patients must have endoscopic or radiographic confirmed Crohn's Disease.
• Patients must have a Pediatric Crohn's Disease Activity Index (PCDAI) of at least 31.

You may not qualify if…

• Adolescent women of childbearing potential and / or sexually active unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide), and willing and able to continue contraception for 3 months after the completion of the study.
• Adolescent women who are pregnant or breastfeeding
• Subjects with an ostomy or ileocolic anastomosis from surgery as these operations interfere with the PCDAI assessment
• Subjects taking tacrolimus, cyclosporin, mycophenolate, or anti-TNF-α therapy must be discontinued 4 weeks prior to study initiation.
• Patients with abnormal liver function tests
• Prednisone greater than 10 mg or > 0.2 mg/kg orally

Where it is running

• Penn State University hershey Medical center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.